BioLife Solutions

BLFS · NASDAQ

Price unavailable right now.

No price history for this range.

BLFS analyst rating

HoldConsensus of 6 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold6
Underperform0
Sell0

12-month price target · 9 analysts

Average $31.91

Low: $31.31
High: $34.65

Upgrades and downgrades

The latest rating actions, newest first

BLFS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	Aug 10, 2026	Downgrade	Buy → Hold	—	53%
Stephens & Co.	Jul 27, 2026	Downgrade	Overweight → Equal-Weight	$32.00 → $31.00	50%
Jefferies	Jul 23, 2026	Downgrade	Buy → Hold	$30.00 → $31.00	67%
TD Cowen	Jul 23, 2026	Downgrade	Buy → Hold	$33.00 → $31.00	68%
Lake Street	Jul 22, 2026	Downgrade	Buy → Hold	$33.00 → $31.00	27%
HC Wainwright & Co.	Jul 22, 2026	Downgrade	Buy → Neutral	$32.00 → $31.00	40%
HC Wainwright & Co.	Dec 29, 2025	Maintains	Buy	$32.00	40%
HC Wainwright & Co.	Nov 24, 2025	Maintains	Buy	$32.00	40%

The case for and against

Updated Oct 3, 2026

Bull case

BioLife Solutions is supported by improving fundamentals, with 2Q26 revenue of $28.5 million, up 21% year over year, and adjusted operating income of $3.1 million versus a loss in 2Q25, showing meaningful profitability leverage in the core business. The outlook is further strengthened by expected 3Q26E revenue of $29.5 million and full-year 2026E revenue of $74.7 million, reflecting 21% growth, as the company benefits from a refocused portfolio centered on higher-margin cell processing and CryoStor. The pending acquisition by Repligen adds strategic validation, and management cited at least $20 million of year-one synergies and at least 5 cents of year-one EPS accretion, reinforcing confidence in BioLife’s underlying asset quality and growth trajectory.

Bear case

BioLife Solutions is facing a cautious outlook because its fundamentals show only modest operating improvement despite a still-narrow business mix, with Cell Processing and CryoStor driving most revenue and gross margin slipping to 64% from 65% in the second quarter. Although biopreservation media is used in about 250 U.S. clinical trials, including over 30 Phase 3 trials, the company remains exposed to regulatory risk, competition from larger players, and lack of profitability, which can limit durable standalone upside. Its $113.1 million in cash and equivalents and $7.4 million in adjusted EBITDA provide some cushion, but the pending Repligen acquisition and expected close in 4Q26 suggest the investment case is more event-driven than rooted in long-term independent growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.